Patient Characteristics

Our study group consisted of 24 metastatic NSCLC patients treated with immune checkpoint blockade as a standard of care (n=19) or in the setting of a clinical trial (n=5) between October 2014 and August 2016 at Johns Hopkins Sidney Kimmel Cancer Center. In parallel, we evaluated 14 patients with stage I-IIIA surgically resectable NSCLC that received anti-PD1 therapy in the setting of a neoadjuvant nivolumab clinical trial (15). The studies were conducted in accordance with the Declaration of Helsinki, were approved by the Institutional Review Board (IRB) and patients provided written informed consent for sample acquisition for research purposes. Clinical characteristics for all patients are summarized in Supplementary Table S1.